Unicorns may get most of the IPO headlines. But as far as some hedge funds are concerned, healthcare — especially fledgling biopharma companies — is where the action is when it comes to new issues.
In 2019, 69 healthcare IPOs raised $9.2 billion, according to Renaissance Capital, a provider of institutional pre-IPO research.
